You are here: Industry Insights > Inlyta

News List

Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib) prnasia
April 29, 2021
Alphamab Oncology announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to evaluate the efficacy and safety of KN046 in combination with Inlyta® (axitinib) for the first-line treatment of NSCLC.
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta pharmatimes
August 28, 2020
MSD’s Keytruda (pembrolizumab) in combination with Pfizer's Inlyta (axitinib) has been turned down by NICE as first-line treatment for patients with advanced renal cell carcinoma (RCC).
FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma drugs
May 15, 2019
FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma.
Keytruda combo set to become “standard of care” in kidney cancer pharmaphorum
February 19, 2019
Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a price advantage over BMS’ rival drug.....
Merck Group and Pfizer announce positive results for combo therapy for RCC pharmaceutical-technology
February 19, 2019
Pfizer and German-based Merck Group have published promising interim results from their Phase III JAVELIN Renal 101 trial evaluating the efficacy and safety of ....
Keytruda/Inlyta combo shows significant survival benefit in kidney cancer trial pharmatimes
October 25, 2018
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS)...
After Trial Failure, Pfizer's Inlyta Unlikely to Replace Sutent for Kidney Cancer biospace
April 12, 2018
An Independent Monitoring Committee recommended that Pfizer halt the Phase III ATLAS trial of Inlyta (axitinib) because it wasn’t proving effective.
Pfizer's Inlyta fails to prolong disease-free survival in Phase III study of patients at risk of recurrent kidney cancer firstwordpharma
April 11, 2018
Pfizer on Tuesday announced that it will halt a late-stage study evaluating Inlyta (axitinib) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy